Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Stopped early · Phase 2
Conditions studied: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
In brief
Cilengitide may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for glioblastoma multiforme. This phase II trial is studying how well cilengitide works in treating patients who are undergoing surgery for recurrent or progressive glioblastoma multiforme.
Key facts
- Study ID
- NCT00112866
- Run by
- National Cancer Institute (NCI)
- People needed
- 30
- Starts
- 2005-01-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2017-06-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed intracranial glioblastoma multiforme (GBM)
- Original diagnosis of low-grade glioma with subsequent histological confirmation of GBM allowed
- Recurrent disease
- Failed prior radiotherapy
- Must require a surgical procedure (gross total or near gross total resection) for tumor removal
- Performance status - Karnofsky 60-100%
- White Blood Count (WBC) ≥ 3,000/mm\^3
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hemoglobin ≥ 10 g/dL (transfusion allowed)
- Serum glutamic oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN)
- Bilirubin < 2 times ULN
- Creatinine < 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception during and for ≥ 2 weeks after study participation (for female patients) or for 3 months after study participation (for male patients)
- No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No active infection
- No other significant uncontrolled medical illness that would preclude study participation
- At least 3 weeks since prior interferon
- No prior cilengitide
- No other prior targeted antiangiogenic treatment (e.g., vatalanib, SU5416, or thalidomide)
- No concurrent anticancer immunotherapy
- No concurrent routine prophylactic filgrastim (G-CSF)
- At least 2 weeks since prior vincristine
Where it is running
- North American Brain Tumor Consortium — Watertown, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.